A Safety and Efficacy Study of Xolair in Peanut Allergy

NCT00086606 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergy

Interventions

DRUG: Xolair (omalizumab)

Sponsor

Genentech, Inc.